Halozyme Therapeutics Inc (HALO) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Halozyme Therapeutics Inc   (NASDAQ: HALO)


Halozyme Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Halozyme Therapeutics Inc's ROI in the third quarter of 2026?
Halozyme Therapeutics Inc achieved a return on average invested assets (ROI) of 19.64 % in its third quarter of 2026, this is above HALO's average return on investment of -15.14%.
Halozyme Therapeutics Inc s investments during the 12 months ending in the third quarter of 2026 are valued at $2 billion

ROI fell compared to the second quarter of 2026, despite the net income growth of 7.45% from the second quarter of 2026.

Within the Healthcare sector 54 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 387, from total ROI ranking in the second quarter of 2026 at 393.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 35.93 % 4.75 % 1.86 % 2.92 % 1.37 %
Y / Y Net Income Change TTM -18.48 % -25.78 % -11.04 % 15.64 % 334.63 %
Investment (TTM) in Millions 2,997 2,233 2,310 2,348 1,384
Return On Investment (TTM) 19.64 % 19.99 % 17.53 % 16.47 % 32.75 %
HALO's Overall Ranking # 387 # 393 # 138 # 166 #
Seq. Investment Change TTM 19.5 % 3.94 % 3.42 % 5.83 % -7.91 %
Seq. Net Income Change TTM 17.37 % 18.56 % 10.08 % -46.79 % 6.86 %
Net Income (TTM) in Millions 485 414 349 317 595

HALO Company Profile >> Back to HALO Roi Comparisons >> See Annual HALO Return On Investment



Return On Investment HALO's Ranking
Within: No.
Industry # 10
Sector # 55
Overall # 387

Return On Investment Statistics
High Average Low
43.26 %
-15.14 %
-104.83 %
(Mar 31 2022)   (Dec 31 2013)







Financial Statements
Halozyme Therapeutics Inc's III. Quarter Investments $ 2,997 Millions HALO's Balance sheet
Halozyme Therapeutics Inc's III. Quarter Income $ 247 Millions Quarterly HALO's Income Statement
HALO's Income by Division See HALO's Income by Division


HALO Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 2,348 1,924 1,621 1,663 987
Y / Y Investment Growth 22.03 % 18.73 % -2.51 % 68.4 % 522.74 %
Net Income in Millions 317 444 282 202 403
Y / Y Net Income Growth -28.64 % 57.71 % 39.31 % -49.81 % 211.97 %
Annual Return On Investment 13.49 % 23.08 % 17.37 % 12.16 % 40.79 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 13.49 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
HALO's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for HALO's Competitors
Subscribers only: Roi for Halozyme Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for HALO's Customers

Other Ratios
HALO's Roa HALO's Inventory Turnover Ratio HALO's Growth Rates HALO's Dividend Statistics
HALO's Profitability Ratios HALO's Asset Turnover Ratio HALO's Dividend Growth
HALO's Roe HALO's Valuation Ratios HALO's Financial Strength Ratios HALO's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %

Date modified: 2026-11-09T06:45:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.